Neuropeptide Alterations in the Infundibular Nucleus of Huntington's Disease Patients

Journal of Neuroendocrinology

Volumn 25, Issue 2, 2013, Pages 198-205

  Van Wamelen, D J ^a,b   Aziz, N A ^b   Anink, J J ^a   Roos, R A C ^b   Swaab, D F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cocaine and amphetamine regulated transcript; Huntington's disease; Hypothalamus; Infundibular nucleus; Neuropeptide Y

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; AMPHETAMINE; COCAINE; MESSENGER RNA; NEUROPEPTIDE; NEUROPEPTIDE Y;

ADULT; AGED; ARCUATE NUCLEUS; ARTICLE; CELL LOSS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MELANOCYTE; NERVE CELL; PARAVENTRICULAR NUCLEUS; PATHOLOGY; PRIORITY JOURNAL; THALAMUS VENTRAL NUCLEUS; WEIGHT REDUCTION;

ADULT; AGED; ALPHA-MSH; ARCUATE NUCLEUS; AUTOPSY; CASE-CONTROL STUDIES; FEMALE; HUMANS; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEURONS; NEUROPEPTIDE Y; NEUROPEPTIDES;

EID: 84873044676     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2012.02379.x     Document Type: Article

References (28)

1. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008; 23: 1491-1504.
2. Aziz NA, Swaab DF, Pijl H, Roos RA. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 2007; 18: 223-251.
3. Swaab DF. The human hypothalamus: basic and clinical aspects, part I: nuclei of the human hypothalamus. In: Aminoff MJ, Boller F, Swaab DF, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier, 2003.
4. Fekete C, Lechan RM. Neuroendocrine implications for the association between cocaine- and amphetamine regulated transcript (CART) and hypophysiotropic thyrotropin-releasing hormone (TRH). Peptides 2006; 27: 2012-2018.
5. Menyhert J, Wittmann G, Lechan RM, Keller E, Liposits Z, Fekete C. Cocaine- and amphetamine-regulated transcript (CART) is colocalized with the orexigenic neuropeptide Y and agouti-related protein and absent from the anorexigenic a-melanocyte-stimulating hormone neurons in the infundibular nucleus of the human hypothalamus. Endocrinology 2007; 148: 4276-4281.
6. Kotliarova S, Jana NR, Sakamoto N, Kurosawa M, Miyazaki H, Nekooki M, Doi H, Machida Y, Wong HK, Suzuki T, Uchikawa C, Kotliarov Y, Uchida K, Nagao Y, Nagaoka U, Tamaoka A, Oyanagi K, Oyama F, Nukina N. Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J Neurochem 2005; 93: 641-653.
7. van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, Woodman B, Wamsteeker JI, Smith R, Deierborg T, Kuhar MJ, Bates GP, Mulder H, Erlanson-Albertsson C, Morton AJ, Brundin P, Petersén A, Björkqvist M. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008; 29: 41-51.
8. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577.
9. Bewick GA, Dhillo WS, Darch SJ, Murphy KG, Gardiner JV, Jethwa PH, Kong WM, Ghatei MA, Bloom SR. Hypothalamic cocaine- and amphetamine-regulated transcript (CART) and agouti-related protein (AgRP) neurons coexpress the NOP1 receptor and nociceptin alters CART and AgRP release. Endocrinology 2005; 146: 3526-3534.
10. Goldstone AP, Unmehopa UA, Bloom SR, Swaab DF. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J Clin Endocrinol Metab 2002; 87: 927-937.
11. Légrádi G, Lechan RM. Agouti-related protein containing nerve terminals innervate thyrotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology 1999; 140: 3643-3652.
12. van der Sluis PJ, Pool CW, Sluiter AA. Press-blotting on gelatin-coated nitrocellulose membranes. A method for sensitive quantitative immunodetection of peptides after gel isoelectric focusing. J Immunol Methods 1987; 104: 65-71.
13. Zhou JN, Riemersma RF, Unmehopa UA, Hoogendijk WJ, van Heerikhuize JJ, Hofman MA, Swaab DF. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001; 58: 655-662.
14. Lucassen PJ, Goudsmit E, Pool CW, Mengod G, Palacios JM, Raadsheer FC, Guldenaar SE, Swaab DF. In situ hybridization for vasopressin mRNA in the human supraoptic and paraventricular nucleus: quantitative aspects of formalin-fixed paraffin-embedded tissue sections as compared to cryostat sections. J Neurosci Methods 1995; 57: 221-230.
15. Liu CQ, Shan L, Balesar R, Luchetti S, van Heerikhuize JJ, Luo JH, Swaab DF, Bao AM. A quantitative in situ hybridization protocol for formalin-fixed paraffin-embedded archival post-mortem human brain tissue. Methods 2010; 52: 359-366.
16. Mihály E, Fekete C, Tatro JB, Liposits Z, Stopa EG, Lechan RM. Hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons in the human hypothalamus are innervated by neuropeptide Y, agouti-related protein, and alpha-melanocyte-stimulating hormone. J Clin Endocrinol Metab 2000; 85: 2596-2603.
17. Aziz NA, Pijl H, Frölich M, Roelfsema F, Roos RA. Altered thyrotropic and lactotropic axes regulation in Huntington's disease. Clin Endocrinol 2011; 73: 540-545.
18. van Wamelen DJ, Aziz NA, Anink JJ, Roos RA, Swaab DF. Paraventricular nucleus neuropeptide expression in Huntington's disease patients. Brain Pathol 2012; 22: 654-661.
19. Björkqvist M, Leavitt BR, Nielsen JE, Landwehrmeyer B, Ecker D, Mulder H, Brundin P, Petersén A. Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov Disord 2007; 22: 1952-1954.
20. Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G, Petersén A. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol 2010; 120: 777-788.
21. Kremer HP, Roos RA, Dingjan G, Marani E, Bots GT. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 1990; 49: 371-382.
22. Timmers HJ, Swaab DF, van de Nes JA, Kremer HP. Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntington's disease patients. Brain Res 1996; 728: 141-148.
23. Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, Miljic D, Milic N, Glodic J, Dieguez C, Casanueva FF, Kostic V. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur J Endocrinol 2004; 151: 451-455.
24. Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN. Energy balance in early-stage Huntington disease. Am J Clin Nutr 2005; 81: 1335-1341.
25. Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 2000; 47: 64-70.
26. Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest 2011; 121: 493-499.
27. Brakch N, Rist B, Beck-Sickinger AG, Goenaga J, Wittek R, Bürger E, Brunner HR, Grouzmann E. Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations. Biochemistry 1997; 36: 16309-16320.
28. Winsky-Sommerer R, Benjannet S, Rovère C, Barbero P, Seidah NG, Epelbaum J, Dournaud P. Regional and cellular localization of the neuroendocrine prohormone convertases PC1 and PC2 in the rat central nervous system. J Comp Neurol 2000; 424: 439-460.